Earnings summaries and quarterly performance for Inspire Medical Systems.
Executive leadership at Inspire Medical Systems.
Timothy P. Herbert
Detailed
Chief Executive Officer, President, and Chair
CEO
BK
Bryan K. Phillips
Detailed
SVP, General Counsel, Chief Compliance Officer and Corporate Secretary
CW
Carlton W. Weatherby
Detailed
Chief Strategy and Growth Officer
JP
Jason P. Kelly
Detailed
Chief Manufacturing and Quality Officer
JC
John C. Rondoni
Detailed
Chief Product & Innovation Officer
MJ
Melissa J. Mann
Detailed
Chief People Officer
RA
Randall A. Ban
Detailed
Executive Vice President, Patient Access and Therapy Development
RJ
Richard J. Buchholz
Detailed
Chief Financial Officer
Board of directors at Inspire Medical Systems.
CM
Casey M. Tansey
Detailed
Director
CB
Cynthia B. Burks
Detailed
Director
DG
Dana G. Mead, Jr.
Detailed
Director
GL
Gary L. Ellis
Detailed
Lead Independent Director
GG
Georgia Garinois-Melenikiotou
Detailed
Director
MJ
Myriam J. Curet, M.D.
Detailed
Director
ST
Shawn T McCormick
Detailed
Director
SG
Shelley G. Broader
Detailed
Director
Research analysts who have asked questions during Inspire Medical Systems earnings calls.
Adam Maeder
Piper Sandler Companies
4 questions for INSP
Also covers: ABT, AXNX, EW +13 more
AP
Anthony Petrone
Mizuho Group
4 questions for INSP
Also covers: ADMA, ALC, BSX +22 more
Brett Fishbin
KeyBanc Capital Markets
4 questions for INSP
Also covers: ALC, COO, ICUI +6 more
DA
Danielle Antalffy
UBS Group AG
4 questions for INSP
Also covers: ABT, ATRC, BAX +15 more
DR
David Rescott
Baird
4 questions for INSP
Also covers: HAE, IRTC, LIVN +7 more
Jonathan Block
Stifel Financial Corp.
4 questions for INSP
Also covers: ALGN, COO, CUTR +11 more
RN
Richard Newitter
Truist Securities
4 questions for INSP
Also covers: AXNX, DXCM, GKOS +18 more
RM
Robert Marcus
JPMorgan Chase & Co.
4 questions for INSP
Also covers: ABT, BAX, BDX +21 more
SS
Shagun Singh Chadha
RBC Capital Markets
4 questions for INSP
Also covers: AXNX, DXCM, GMED +11 more
Travis Steed
Bank of America
4 questions for INSP
Also covers: ABT, AXNX, BAX +19 more
Christopher Pasquale
Nephron Research
3 questions for INSP
Also covers: ALC, AXGN, BSX +12 more
LB
Larry Biegelsen
Wells Fargo & Company
3 questions for INSP
Also covers: ABT, ALC, AXNX +24 more
Michael Polark
Wolfe Research
3 questions for INSP
Also covers: BSX, DXCM, EMBC +11 more
MS
Michael Sarcone
Jefferies
3 questions for INSP
Also covers: ALC, AXGN, CTSO +11 more
Michael Kratky
Leerink Partners
2 questions for INSP
Also covers: AXGN, BBNX, DXCM +6 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
2 questions for INSP
Also covers: ABT, AORT, ATRC +14 more
BN
Brett Netson
Leerink Partners
1 question for INSP
Chris Pasquale
Nephron Research LLC
1 question for INSP
Also covers: ALC, AXGN, BSX +7 more
Kallum Titchmarsh
Morgan Stanley
1 question for INSP
Also covers: ATEC, AXNX, EMBC +5 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for INSP
Also covers: ABT, ALC, BAX +16 more
Mike Kratky
Leerink Partners
1 question for INSP
Also covers: AXGN, DXCM, MDT +4 more
Mike Polark
Wolfe Research, LLC
1 question for INSP
Also covers: BBNX, BSX, DXCM +6 more
Recent press releases and 8-K filings for INSP.
Inspire Medical Systems, Inc. Announces Preliminary Q4 and Full Year 2025 Results, 2026 Guidance, and New CFO
INSP
Earnings
Guidance Update
CFO Change
- Inspire Medical Systems, Inc. announced preliminary, unaudited revenue for Q4 2025 between $268.9 million and $269.1 million, an approximately 12% increase over Q4 2024, and full year 2025 revenue between $911.8 million and $912.0 million, a 14% increase over full year 2024.
- The company provided initial full year 2026 revenue guidance of $1,003 million to $1,013 million, representing a 10% to 11% increase over full year 2025. This outlook does not include any contribution from increased reimbursement at this time.
- Matt Osberg has been appointed as Executive Vice President and Chief Financial Officer, with a start date of January 19, 2026.
3 days ago
Inspire (INSP) Pre-Announces 2025 Revenue, Provides 2026 Guidance, and Announces New CFO
INSP
Guidance Update
Product Launch
CFO Change
- Inspire (INSP) pre-announced full-year 2025 revenue of approximately $912 million.
- The company issued initial revenue guidance for 2026 between $1.003 billion and $1.013 billion, reflecting 10%-11% growth, which excludes any contributions from increased reimbursement.
- The Inspire 5 neurostimulator system launch has been successful, with 100% of physicians trained and 90% of centers on the SleepSync program. The new system reduces procedure time to 30-45 minutes.
- Inspire is actively working with agencies to clarify reimbursement for the Inspire 5 procedure, asserting that 64568 best describes the procedure and is currently being billed.
- Matt Osberg will join Inspire as the new Chief Financial Officer later in January.
3 days ago
Inspire Medical Systems Provides 2025 Revenue Update and 2026 Guidance, Announces New CFO
INSP
Guidance Update
Product Launch
CFO Change
- Inspire pre-announced Q4 and full-year 2025 revenue and provided initial 2026 revenue guidance, which does not include any contributions from increased reimbursement.
- The Inspire V neurostimulator system launch has seen strong adoption, with 100% of physicians trained and reduced procedure times, contributing to significant momentum in Q4 2025.
- The company is actively working to clarify reimbursement for code 64568, which was billed for Inspire V procedures throughout 2025.
- Matt Osberg will join Inspire as the new CFO in late January.
- Inspire is developing future innovations, including Inspire VI for auto sleep detection and a dual-channel device to treat high BMI patients.
3 days ago
Inspire Pre-Announces 2025 Revenue, Provides 2026 Guidance, and Announces New CFO
INSP
Guidance Update
Product Launch
CFO Change
- Inspire pre-announced full-year 2025 revenue of approximately $912 million and provided initial 2026 revenue guidance of $1.003 billion to $1.013 billion, representing 10%-11% growth. This guidance does not include contributions from increased reimbursement.
- The Inspire 5 system has fully launched with high adoption rates, and the company is developing Inspire 6 as a software upgrade for auto sleep detection to improve therapy adherence.
- Inspire is actively working with relevant agencies to clarify reimbursement for the 64568 procedure code, which was billed and paid for Inspire 5 procedures throughout 2025.
- Matt Osberg will join Inspire as the new CFO later in January.
3 days ago
Inspire Medical Systems Announces Preliminary Q4 and Full Year 2025 Results and 2026 Guidance
INSP
Earnings
Guidance Update
Management Change
- Inspire Medical Systems, Inc. anticipates preliminary fourth quarter 2025 revenue to be between $268.9 million and $269.1 million, an approximate 12% increase over the same quarter of 2024.
- Preliminary full year 2025 revenue is expected to range from $911.8 million to $912.0 million, representing an approximate 14% increase over full year 2024.
- The company provided initial full year 2026 revenue guidance of $1,003 million to $1,013 million, which would be a 10% to 11% increase over full year 2025.
- Matt Osberg has been appointed as the new Executive Vice President and Chief Financial Officer, with a start date of January 19, 2026.
3 days ago
Inspire Medical Systems Faces Securities Fraud Lawsuit Following Stock Drop
INSP
Legal Proceedings
Guidance Update
Product Launch
- Inspire Medical Systems (INSP) is facing a class action lawsuit for securities fraud following a more than 32% stock drop on August 5, 2025.
- The lawsuit alleges the company failed to adequately prepare for the launch of its Inspire V device, resulting in significant delays in adoption and weak demand.
- On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by more than 80%.
- This disclosure caused the stock price to drop $42.04 per share, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025.
- Investors have until January 5, 2026, to ask the Court to be appointed to lead the case.
Jan 2, 2026, 2:07 PM
Inspire Medical Systems Faces Securities Fraud Lawsuit Over Inspire V Launch Failures
INSP
Legal Proceedings
Profit Warning
Product Launch
- A securities class action lawsuit has been filed against Inspire Medical Systems (INSP), alleging the company concealed critical operational failures surrounding the launch of its next-generation device, the Inspire V.
- The lawsuit claims Inspire Medical misled investors by assuring "operational readiness" while issues such as delayed Medicare claims processing software updates until July 1, 2025, and an excess inventory of the older Inspire IV device, stalled the Inspire V rollout.
- These alleged concealments led to Inspire Medical slashing its 2025 EPS guidance by over 80% and a $42.04 per share drop, representing a 32.4% decline in stock value.
- The class period for investors is between August 6, 2024, and August 4, 2025, with a Lead Plaintiff Deadline of January 5, 2026.
Jan 1, 2026, 2:00 PM
Inspire Medical Systems Faces Securities Class Action Over Inspire V Launch Issues
INSP
Legal Proceedings
Product Launch
Guidance Update
- Faruqi & Faruqi, LLP is investigating Inspire Medical Systems (INSP), and a federal securities class action has been filed against the company, with a lead plaintiff deadline of January 5, 2026.
- The lawsuit alleges that Inspire Medical made false or misleading statements regarding the Inspire V device, specifically concerning market demand and launch preparedness, impacting investors who purchased securities between August 6, 2024, and August 4, 2025.
- On August 4, 2025, Inspire Medical disclosed significant setbacks for the Inspire V launch, including delayed training for treatment centers, billing and reimbursement issues, weak demand, and excess inventory.
- These issues prompted Inspire Medical to cut its 2025 earnings guidance by over 80%.
- Following these disclosures, Inspire's stock price fell more than 32% on August 5, 2025, wiping out approximately $1.2 billion in market capitalization.
Dec 26, 2025, 3:45 PM
Inspire Medical Systems Faces Securities Class Action Lawsuit
INSP
Legal Proceedings
Guidance Update
Product Launch
- Bernstein Litowitz Berger & Grossmann LLP (BLB&G) filed a securities class action lawsuit against Inspire Medical Systems, Inc. and certain senior executives, covering investors who purchased common stock between August 6, 2024, and August 4, 2025.
- The lawsuit alleges misrepresentations concerning the launch of the Inspire V device, specifically regarding issues with demand, reimbursement codes, and the readiness of treatment centers for training and IT integration.
- The alleged truth became apparent on August 4, 2025, when Inspire announced an 80% reduction in its full-year earnings per share guidance, leading to a 32.4% decline in its common stock price, or $42.04 per share.
Dec 22, 2025, 10:33 PM
Inspire Medical Systems Faces Securities Fraud Lawsuit
INSP
Legal Proceedings
Demand Weakening
Profit Warning
- A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (INSP), alleging the company misled investors by concealing critical operational failures during the launch of its next-generation Inspire V device.
- The lawsuit claims that undisclosed issues, including Medicare claims software failures and an excess inventory of the older Inspire IV device, led to a catastrophic guidance cut and a $42.04 per share stock drop, representing a 32.4% decline in value.
- Investors who purchased INSP securities between August 6, 2024, and August 4, 2025, are part of the Class Period, with a Lead Plaintiff Deadline of January 5, 2026.
Dec 22, 2025, 1:50 PM
Quarterly earnings call transcripts for Inspire Medical Systems.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more